High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: Normalization with metformin and flutamide overcomes the aggravation by oral contraception

Human Reproduction

Volumn 20, Issue 9, 2005, Pages 2457-2462

  Ibáñez, Lourdes ^a   Jaramillo, Adriana Maria ^a   Ferrer, Angela ^a   de Zegher, Francis ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Flutamide; Leukocytosis; Metformin; Oral contraception; Ovarian hyperandrogenism

Indexed keywords

DROSPIRENONE; FLUTAMIDE; GESTODENE; METFORMIN;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MONOTHERAPY; NEUTROPHILIA; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL; SPAIN;

EID: 24144488739     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/dei072     Document Type: Article

References (50)

1. Asunción M, Calvo RM, San Millan JL, Sancho J, Avila S and Escobar-Morreale H (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85,2434-2438.
2. Baumann EE and Rosenfield RL (2002) Polycystic ovary syndrome in adolescence. Endocrinologist 12,333-348.
3. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O and Blumenfeld Z (2004) Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease. J Clin Endocrinol Metab 89,2160-2165.
4. Dandona P, Aljada A, Chaudhuri A and Bandyopadhyay A (2004) Inflammation: The link between insulin resistance, obesity and diabetes. Trends Inmunol 25,4-7.
5. de Leo V, Lanzetta D, D'Antona D, a Marca A and Morgante G (1998) Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 83,99-102.
6. Diamanti-Kandarakis E, Mitrakou A and Raptis S Tolis G and Duleba AJ (1998) The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 83,2699-2705.
7. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ and Nestler JE (2003) Controversies in endocrinology. A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 88,1927-1932.
8. Dunaif A and Thomas A (2000) Current concepts in the polycystic ovary syndrome. Annu Rev Med 52,401-419.
9. Dunaif A, Scott D, Finegood D, Quintana B and Whitcomb R (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81,3299-3306.
10. Elter K, Imir G and Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin addedd to ethynil-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: A randomized controlled study. Hum Reprod 17,1729-1737.
11. Expert Committe on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20,1183-1197.
12. Fernández-Real JM and Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24,278-301.
13. Ferriman D and Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21,1440-1447.
14. Fonseca V, Desouza C, Asnani S and Jialal I (2004) Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25,153-175.
15. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U and Pasquali R (2004) Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol 60 (ii),241-249.
16. Goldfine AB and Kahn CR (2003) Adiponectin: Linking the fat cell to insulin sensitivity. Lancet 362,1431-1432.
17. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R and Lanzone A (2004) Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: A clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89,2817-2823.
18. Ibaáñez L and de Zegher F (2003) Flutamide-metformin to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: Effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 88,4720-4724.
19. Ibaáñez L and de Zegher F (2004a) Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and young women with hyperinsulinemic hyperandrogenism: Opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 89,1592-1597.
20. Ibaáñez L and de Zegher F (2004b) Flutamide-Metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. Hum Reprod 19,1725-1727.
21. Ibátinez L and de Zegher F (2005) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: The key role of metformin at start and after more than one year of therapy. J Clin Endocrinol Metab 90,39-43.
22. Ibaáñez L, Potau N, Zampolli M, Riqué S, Saenger P and Carrascosa A (1997) Hyperinsulinemia and decreased insulin-like growth factor binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab 82,2283-2288.
23. Ibaáñez L, de Zegher F, Francois I and Potau N (1998) Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 83,3558-3662.
24. Ibaáñez L, Valls C, Potau N, Marcos MV and de Zegher F (2000a) Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 85,3526-3530.
25. Ibaáñez L, Potau N, Marcos MV and de Zegher F (2000b) Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in non-obese, adolescent girls: Effect of flutamide. J Clin Endocrinol Metab 85,3251-3255.
26. Ibaáñez L, Valls C, Potau N, Marcos MV and de Zegher F (2001a) Polycystic ovary syndrome after precocious pubarche: Ontogeny of the low birthweight effect. Clin Endocrinol 55,667-672.
27. Ibáñez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F and de Zegher F (2001b) Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 86,3595-3598.
28. Ibáñez L, Valls C, Ferrer A, Ong K, Dunger D and de Zegher F (2002a) Additive effects of insulin-sensitizing and antiandrogen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab 87,2870-2874.
29. Ibáñez L, Valls C, Miró E, Marcos MV and de Zegher F (2002b) Early menarche and subclinical ovarian hyperandrogenism in girls with reduced adult height after low birthweight. J Pediatr Endocrinol Metab 15, 431-433
30. Ibaáñez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV and de Zegher F (2002c) Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: Insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 87,5702-5705.
31. Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D and de Zegher F (2003) Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in non-obese adolescents and young women with ovarian hyperandrogenism. J Clin Endocrinol Metab 88,2600-2606.
32. Ibáñez L, Valls C, Marcos MV, Ong K, Dunger D and de Zegher F (2004a) Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: Effects of prepubertal initiation and postpubertal discontinuation of metformin. J Clin Endocrinol Metab 89,4331-4337.
33. Ibáñez L, Valls C, Cabré S and de Zegher F (2004b) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: The key role of early, lowdose flutamide. J Clin Endocrinol Metab 89,4716-4720.
34. Ibáñez L, Ferrer A, Ong K, Amin R, Dunger D and de Zegher F (2004c) Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 144,23-29.
35. Ibáñez L, Jaramillo A, Ferrer A, Zegher F and de Zegher F (2005) Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod in press.
36. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM and Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86,2453-2455.
37. Libby P (2002) Inflammation and atherosclerosis. Nature 420,868-874.
38. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E and Muggeo M (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85,139-146.
39. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M and Tapanainen JS (2003a) Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88,4649-4654.
40. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H and Tapanainen JS (2003b) Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of non-obese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab 88,148-156.
41. Nestler JE and Jakubowicz DJ (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17αactivity and serum androgens. J Clin Endocrinol Metab 82, 4075-4079.
42. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S and Levine LS (1983) Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data. J Clin Endocrinol Metab 56,320-325.
43. Orio P Jr F, Palomba S, Cascella T, DI Biase S, Manguso F, Tauchmanova' L, Nardo LG, Labella D, Savastano S, Russo T, Zullo F, Colao A and Lombardi G (2005) The increase of leukocytes as a new putative marker of low grade chronic inflammation and early cardiovascular risk in the polycystic ovary syndrome. J Clin Endocrinol Metab 90,2-5.
44. Palep-Singh M, Mook K, Barth J and Balen A (2004) An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care 30,163-165.
45. 5-steroid levels. J Clin Endocrinol Metab 81, 3961-3965.
46. Sjöholm A and Nyström T (2005) Endothelial inflammation in insulin resistance. Lancet 365,610-612.
47. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T and Duman C (2004) Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89,5592-5596.
48. Vidal-Puig A and Moller DE (1997) Insulin resistance: Classification, prevalence, clinical manifestations, and diagnosis. In Azziz R, Nestler JE, and Dewailly D (eds) Androgen Excess Disorders in Women. Lippincott-Raven Publishers, Philadelphia, USA, pp. 227-236.
49. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL and Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112,1796-1808.
50. H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA and Chen H (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112,1821-1830.